|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/137 | (2006.01) |
| A61P 37/00 | (2006.01) | ||
| A61P 37/06 | (2006.01) | ||
| A61K 31/135 | (2006.01) | ||
| A61K 31/138 | (2006.01) | ||
| A61K 31/661 | (2006.01) |
| (11) | Number of the document | 4098256 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22187007.4 |
| Date of filing the European patent application | 2009-12-21 | |
| (97) | Date of publication of the European application | 2022-12-07 |
| (45) | Date of publication and mention of the grant of the patent | 2025-02-26 |
| (46) | Date of publication of the claims translation | 2025-06-10 |
| (30) | Number | Date | Country code |
| 139672 P | 2008-12-22 | US | |
| 218530 P | 2009-06-19 | US | |
| 246715 P | 2009-09-29 | US |
| (72) |
SCHMOUDER, Robert , US
DUMORTIER, Thomas , CH
DAVID, Olivier , CH
LOOBY, Michael , CH
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Vilija VIEŠŪNAITĖ,
Advokatų profesinė bendrija "TRINITI JUREX", Vilniaus g. 31, LT-01402 Vilnius,
LT
|
| (54) | S1P receptorių agonisto dozavimo režimas |
| DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST |
| Payment date | Validity (years) | Amount | |
| 2025-11-21 | 17 | 347.00 EUR |
| 2026-12-21 |